{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:transthyretin-directed-medicines",
  "owner": "cardio",
  "kind": "drug",
  "slug": "transthyretin-directed-medicines",
  "name": "Transthyretin stabilizers and transthyretin-directed RNA interaction medicines",
  "aliases": [
    "Transthyretin Stabilizer",
    "Transthyretin Stabilizers",
    "Transthyretin-directed small interfering RNA",
    "Transthyretin-directed RNA Interaction"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "This page groups two kinds of medicine made for transthyretin amyloidosis, in which the protein transthyretin (TTR) forms deposits in tissues. The US labels use their own words. The tafamidis label calls the medicine a selective stabilizer of TTR, and the Attruby (acoramidis) label calls it a transthyretin stabilizer that slows the breakup of the TTR tetramer into single units. The Amvuttra (vutrisiran) label calls it a transthyretin-directed small interfering RNA that causes degradation of TTR messenger RNA, which reduces TTR protein and its deposits in tissues. Each medicine has its own page, where its label indication is recorded. This is the class page: it holds no trial results and no instructions.",
  "summary_technical": "Class page. The name uses the RxClass class names, Transthyretin Stabilizer and Transthyretin-directed RNA Interaction; the word silencer does not appear in the labels or RxClass records read, and the Amvuttra label says small interfering RNA. No MeSH descriptor fits the group. RxClass (FDASPL source, read 2026-11-19) lists, for acoramidis, the established pharmacologic class Transthyretin Stabilizer (EPC) and the mechanism class Transthyretin Stabilizers (MoA), and for vutrisiran the classes Small Interfering RNA and Transthyretin-directed RNA Interaction (both EPC); the two medicines are filed under this page on that evidence. RxClass returned no class for tafamidis, so its filing rests on its label sentence that calls tafamidis a selective stabilizer of TTR. A small interfering RNA medicine that acts on a different target is not in this group. No trial result, dose or instruction is recorded.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-19",
  "last_evidence_check": "2026-11-19",
  "next_review_due": "2027-05-19",
  "identifiers": [],
  "navigation": {
    "cardio": {
      "system": [
        "heart"
      ],
      "condition-area": [
        "heart-failure"
      ]
    }
  },
  "payload": {
    "level": "class",
    "mechanism": "Two label wordings: a stabilizer of transthyretin (tafamidis and acoramidis labels; the acoramidis label says it slows dissociation of the TTR tetramer into monomers), and a small interfering RNA that causes degradation of TTR messenger RNA through RNA interference (Amvuttra label)."
  },
  "content_digest": "d393cc1ab60f574e35f6396367de11a633cf80ea699d0745fb4b3d17789fea02",
  "review": {
    "content_digest": "d393cc1ab60f574e35f6396367de11a633cf80ea699d0745fb4b3d17789fea02",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "The US labels of the member medicines list the cardiomyopathy of transthyretin-mediated amyloidosis as an indication",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:cardiac-amyloidosis",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": [
      {
        "predicate": "subtype_of",
        "label": "Has subtype",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:acoramidis",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-2698312-2026-11-19",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "subtype_of",
        "label": "Has subtype",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:tafamidis",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:openfda-label-1b4121ee-a733-4456-a917-be2603477839-2026-10-30",
          "locator": "results[0].mechanism_of_action[0]"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "subtype_of",
        "label": "Has subtype",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:vutrisiran",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-2604578-2026-11-19",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[4].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ]
  },
  "page_path": "drugs/transthyretin-directed-medicines/",
  "context_path": "api/v1/context/cardio--transthyretin-directed-medicines.md"
}
